Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spyre Therapeutics ( (SYRE) ) has provided an announcement.
On June 17, 2025, Spyre Therapeutics announced positive interim Phase 1 results for its novel monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These antibodies showed a favorable safety profile and extended half-life, supporting less frequent dosing. The company also initiated the SKYLINE-UC platform trial for ulcerative colitis and unveiled the SKYWAY-RD basket trial for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. These developments mark a significant step in Spyre’s clinical pipeline, potentially enhancing its position in the biotechnology industry and offering promising treatment options for immune-mediated diseases.
The most recent analyst rating on (SYRE) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
Spyre Therapeutics is facing significant financial challenges with consistent revenue and profitability issues. Its strong equity position is overshadowed by operational cash flow problems and persistent losses. Technically, the stock is under bearish pressure, and the valuation is complicated by a negative P/E ratio and lack of dividends. These factors combined result in a low overall stock score, reflecting the high-risk nature of investing in this biotechnology company.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.
Average Trading Volume: 625,524
Technical Sentiment Signal: Sell
Current Market Cap: $1.04B
See more insights into SYRE stock on TipRanks’ Stock Analysis page.